Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 9/20 | 0.44 |
| ▸ | USP1 | O94782 | 3/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16872708 | 0.86 | USP1 (0.42) | DDR1USP1PDE2APOLBALOX5AP | |
| SCHEMBL16885087 | 0.84 | USP1 (0.41) | USP1ALOX5APFEN1 | |
| SCHEMBL28002839 | 0.79 | KDM1A (0.43) | PTGDR2 | |
| SCHEMBL16667011 | 0.78 | ALOX5AP (0.38) | DDR1USP1PDE2AALOX5APFEN1 | |
| SCHEMBL16872730 | 0.76 | TLR7 (0.45) | DDR1USP1PDE2AWDR48 | |
| SCHEMBL9952750 | 0.74 | ILK (0.49) | DDR1PDE2A | |
| SCHEMBL9951989 | 0.74 | UTRN (0.49) | DDR1POLBMEN1KMT2A | |
| SCHEMBL16885099 | 0.74 | CYP1A2 (0.40) | USP1ALOX5APFEN1KMT2A | |
| SCHEMBL20628137 | 0.74 | ALOX5AP (0.46) | DDR1POLBALOX5APFEN1KMT2A | |
| SCHEMBL9959692 | 0.74 | PDE2A (0.53) | DDR1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2865671-B1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9328121-B1 | Fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9328121-B1 | Fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20160102100-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160102100-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9260436-B2 | Fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9260436-B2 | Fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20150191474-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-09 | — | — | US | disclosed |
| US-20150191474-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-09 | — | — | US | disclosed |
| EP-2865671-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2015-04-29 | — | — | EP | disclosed |
| CN-104395298-A | Fused heterocyclic compound | SUMITOMO CHEMICAL CO | 2015-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102100-A1 | FUSED HETEROCYCLIC COMPOUND | NR4A1, CYP4B1, NR1H4 | DDR1 3473/4885USP1 2651/4885PDE2A 4442/4885 |
| US-20150191474-A1 | FUSED HETEROCYCLIC COMPOUND | NR4A1, NR0B1, NR0B2 | DDR1 2509/4885USP1 2314/4885PDE2A 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.